Aptevo Therapeutics Revenue 2014-2022 | APVO

Aptevo Therapeutics revenue from 2014 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Aptevo Therapeutics Annual Revenue
(Millions of US $)
2021 $12
2020 $4
2019 $
2018 $23
2017 $15
2016 $10
2015 $34
2014 $46
2013 $
Aptevo Therapeutics Quarterly Revenue
(Millions of US $)
2022-03-31 $3
2021-12-31 $4
2021-09-30 $3
2021-06-30 $3
2021-03-31 $2
2020-12-31 $2
2020-09-30 $1
2020-06-30 $0
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31 $6
2018-09-30 $6
2018-06-30 $7
2018-03-31 $4
2017-12-31 $3
2017-09-30 $6
2017-06-30 $4
2017-03-31 $2
2016-12-31 $-11
2016-09-30 $3
2016-06-30 $10
2016-03-31 $8
2015-12-31
2015-09-30 $7
2015-06-30 $7
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.299B 9.94
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.420B 16.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.085B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.716B 0.00
Emergent Biosolutions (EBS) United States $1.842B 7.89
Arcus Biosciences (RCUS) United States $1.368B 34.69
Myovant Sciences (MYOV) United Kingdom $0.984B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.517B 0.00
Gelesis Holdings (GLS) United States $0.358B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.10
SQZ Biotechnologies (SQZ) United States $0.095B 0.00